Evidence map›Paper›PMID 31908156›Full record

Observational studyCancer medicine2020

Evaluation of the diagnostic value of circulating tumor cells with CytoSorter

Lidan Jin, Wenhe Zhao, Jun Zhang, Wenjun Chen, Tan Xie, Linbo Wang, Wanhung Fan, Shuduo Xie, Jianguo Shen, Heming Zheng and 6 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Impact of Nanomedicine in Women's Metastatic Breast Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  10. Identification of circulating tumor cells captured by the FDA-cleared ParsortixJournal of experimental & clinical cancer research : CR · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Lidan JinDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.ORCID 0000-0002-8985-3362
Wenhe ZhaoDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Jun ZhangDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Wenjun ChenDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Tan XieDepartment of Nursing, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Linbo WangDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Wanhung FanHangzhou Watson Biotech, Hangzhou, China.
Shuduo XieDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Jianguo ShenDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Heming ZhengDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Wenxian HuDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Qun WeiDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Minjun DongDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Qinchun WangDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Jun ShenDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Yongcheng LiuDepartment of Surgical Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University College of Medicine, Hangzhou, China.
Sir Run Run Shaw Hospital · CNHangzhou DAC Biotech (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn this study, we aimed to investigate the viability of utilizing CytoSorter

methodsA total of 366 females patients suspected of having BC and 30 healthy female volunteers were enrolled in this study. CTCs were enriched by CytoSorter

resultsBased on the biopsy results, 130 BC patients at different cancer stages and 236 patients with BBD were enrolled in the study. Seven subjects were dropped out from the study. CTCs were detected in 109 of 128 BC patients, in one of 29 healthy volunteers, and in 37 of 232 patients with BBD. Maximum CTC counts detected in BC patients, healthy volunteers, and patients with BBD were 8, 1, and 4, respectively. Statistical analysis showed CTCs could be used to distinguish BC patients from healthy volunteers and patients with BBD (P < .0001). Circulating tumor cells were statistically associated with patients' cancer stage (P = .0126), tumor size (tumor node metastasis [TNM] T stage, P = .0253), cancer type (invasive vs noninvasive, P = .0141), and lymph node metastasis (P = .0436). More CTCs were found in patients at advanced cancer stage or TNM T stage and in patients with invasive tumor or lymph node metastasis. Furthermore, CTC detection rates in BC patients at Tis and T1-4 stages were 50%, 81.67%, 91.07%, 100%, and 100%, respectively. When the CTC cut-off value was set to 2, the ROC curve gave an area under the curve (AUC) of 0.86 with a specificity and sensitivity of 95.4% and 76.56%, respectively. Taken together, CTCs could be used as a diagnostic aid in assistance of cancer screening and staging.

conclusionCirculating tumor cells were successfully isolated in BC patients using CytoSorter

Indexed as

AdolescentAdultAgedBiopsyBreastBreast NeoplasmsCase-Control StudiesCell CountCell Line, TumorCell SeparationDiagnosis, DifferentialEarly Detection of CancerFeasibility StudiesFemaleHealthy VolunteersHumansbreast cancercancer stagingcirculating tumor cellsearly diagnosisscreening

Identifiers

PMID31908156
PMCPMC7050089
OpenAlexW2999938665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.